Streetinvesting.com: Progressive Following on Oscient Pharmaceuticals Corp.

Apr 16, 2008 (M2 PRESSWIRE via COMTEX) -- OSCI | news | PowerRating | PR Charts -- Streetinvesting.com has now resumed our progressive review of Oscient Pharmaceuticals Corp. (NASDAQ:OSCI) as it fell down $0.31 on over 250,000 more than double its average volume early trading Wednesday, April 16, 2008. Based on the Company's most recent news release; we will be progressively reviewing the impact of the markets and the effects of their developments. We will be providing updates and analyst opinions as new stories unfold.

Make sure to visit www.streetinvesting.com to keep updated and signup for free with no credit card for market reports and analytical plays.

Our research resources have been aimed towards the US Large Caps and the various prospective companies therein Oscient Pharmaceuticals Corp. was among those that we have been closely examining due to their recent news and trading patterns. Sign up at www, streetinvesting.com for more information on the company mentioned herein.

April 16, 2008 -- Oscient Pharmaceuticals Corporation announced preliminary revenue results for the first quarter ended March 31, 2008. For the first quarter of 2008, the Company expects to record total revenues of approximately $18.5 million, with more than two-thirds derived from sales of ANTARA (fenofibrate) capsules. The Company expects its total cash, including restricted cash and cash equivalents, as of March 31, 2008, to be approximately $42 million.

Oscient Pharmaceuticals Corporation is a commercial-stage pharmaceutical company marketing two FDA-approved products in the United States: ANTARA (fenofibrate) capsules, a cardiovascular product and FACTIVE (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ANTARA is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE is approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. Oscient promotes ANTARA and FACTIVE through a national sales force calling on primary care physicians, cardiologists, endocrinologists and pulmonologists. The Company also has a novel, late-stage antibiotic candidate, Ramoplanin, for the treatment of Clostridium difficile-associated disease (CDAD).

Streetinvesting.com will continue to follow the progress of this company following their most recent news announcement. Visit www.streetinvesting.com and signup free for our financial market services.

At Streetinvesting.com, we bring our knowledge of the marketplace and investment opportunities directly to our subscribers. As an aggressive-growth research company, our strength and goal is bringing distinctive trading opportunities and investment philosophies to investors seeking a different and unique approach to investment ideas. That's our goal. That's what we do. We are "The Word on the Street".

Let us become your number one portal for research and information on the global markets.

To continue with the more in-depth analysis, please visit www.streetinvesting.com for a complimentary subscription to access this report and other related articles. Please note that membership does not require credit card information.

All material herein was prepared by Streetinvesting.com, (Street Investing) based upon information believed to be reliable. The information contained herein is not guaranteed by Streetinvesting.com to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Streetinvesting.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Streetinvesting.com may receive compensation in cash or shares from independent third parties or from the companies mentioned.

Streetinvesting.com's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value.

Streetinvesting.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Streetinvesting.com undertakes no obligation to update such statements.

CONTACT: Streetinvesting.com WWW: http://www.streetinvesting.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index